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AIMS
To review the pharmacokinetics of rFVIIa in various patient populations,and to discuss the differences observed between groups.
METHODS
Based on a registry of Novo Nordisk studies,14 studies evaluating rFVIIa pharmacokinetics following single and multiple bolus
administration in healthy volunteers,adult and paediatric patients with congenital haemophilia and inhibitors,patients undergoing
liver surgery and in patients with cirrhosis,inherited FVII deﬁciency,upper gastrointestinal bleeding or severe trauma were identiﬁed.
Data on rFVIIa PK,analyzed with noncompartmental and population pharmacokinetic methods,were extracted.
RESULTS
Plasma clearance was a more robust parameter than half-life for comparing rFVIIa pharmacokinetics between groups.In healthy
volunteers and patients with no or low-level bleeding (e.g.adults with haemophilia,nonbleeding patients with cirrhosis),plasma
clearance was relatively low (30–40 ml kg-1 h-1).In children with haemophilia and adults with high-level bleeding (e.g.cirrhotic patients
undergoing orthotopic liver transplantation or resection) and patients with congenital FVII deﬁciency,plasma clearance was relatively
higher (60–90 ml kg-1 h-1).
CONCLUSIONS
Comparison of plasma clearance rates in different patient populations suggested that subjects fall into two distinct groups.These
differences may have clinical implications in terms of how to adapt the rFVIIa dosing regimen,depending on the expected bleeding
rate/blood loss and underlying disease.
Introduction
RecombinantactivatedfactorVII(rFVIIa,NovoSeven®;Novo
Nordisk A/S, Bagsværd, Denmark) is established for the
treatment of bleeding episodes and for the prevention of
bleeding during surgery or invasive procedures in patients
with congenital haemophilia A and B with inhibitors to
coagulationfactorsVIII(FVIII)orIX(FIX)orinthoseexpected
tohaveahighanamnesticresponsetoFVIIIorFIX,acquired
haemophilia, congenital FVII deﬁciency or Glanzmann’s
thrombasthenia refractory to platelet transfusions.
In addition to these indications, the therapeutic
potential of rFVIIa has been explored for a number of criti-
cal bleeding situations. For example, rFVIIa successfully
reversed coagulopathy in 75% (61/81) of patients with
bleeding and coagulopathy resulting from a number of
different causes, including acute traumatic haemorrhage
and traumatic brain injury [1]. In a multicentre, random-
ized,controlled Phase II trial,rFVIIa reduced red blood cell
(RBC) transfusion requirements and the need for massive
transfusion vs. placebo in patients with severe blunt
trauma [2] and a conﬁrmatory Phase III trial evaluating
rFVIIa for the treatment of traumatic haemorrhage is
ongoing.In addition rFVIIa has been shown to reduce hae-
matoma growth in intracerebral haemorrhage, although
this reduction did not translate into improved long-term
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on rFVIIa use in nonhaemophilia indications has been
published [4,5].
Atpharmacologicaldoses,rFVIIabindstothesurfaceof
locallyactivatedplateletsfollowingvascularinjury,directly
activatingfactorX,andtherebyenhancinglocalizedthrom-
bin generation and formation of a stable ﬁbrin clot only at
thesiteofvascularinjury[6].Althoughnotthefocusofthis
paper,pharmacokineticsarerelevantforanunderstanding
of drug safety and the incidence of drug related adverse
events [7].In addition,by improving the understanding of
drugdistributionandeliminationprocessesofrFVIIa,phar-
macokinetics may offer insight into the design of optimal
therapeutic regimens for this unique agent,particularly in
casesofsevereorpoorlycharacterizedbleeding.Thispaper
aims to address this by reviewing pharmacokinetic data
from clinical studies of rFVIIa following single and multiple
i.v.bolusadministration.Theﬁndingsandtheirrelevanceto
the therapeutic use of rFVIIa are discussed.
Overview of studies evaluating the
pharmacokinetics of rFVIIa
The pharmacokinetics of rFVIIa have been assessed in
studiesofhealthyvolunteersandinstudiesofpatientswith
nooronlyminortissueinjuriesandlowassociatedlevelsof
bleeding, as well as in patients with more pronounced
tissue injuries and bleeding, a distinction that appears to
have implications for the pharmacokinetics of rFVIIa.
Patientsreceivedeitherasinglei.v.bolus[8–17]ormultiple
i.v.boluses of rFVIIa [2,18–20] (details of individual studies
are shown in Table 1).Pharmacokinetic studies were iden-
tiﬁed based on a registry of Novo Nordisk ﬁles.
Inallstudies,pharmacokineticassessmentswerebased
on the FVII coagulant activity (FVII:C) assay, a one-stage
assay using thromboplastin tissue factor,which quantiﬁes
FVII clotting activity in plasma (Capio Diagnostik A/S,
Denmark) [21]. The lower limit of quantiﬁcation for the
assayis0.06 U ml
-1,andtheassayprecisionis10%CV.Since
thisassaydoesnotdistinguishendogenousFVII/FVIIafrom
rFVIIa, baseline plasma FVII:C (i.e.before administration of
rFVIIa) was taken into account in the pharmacokinetic
analyses. Some studies also used the FVIIa clot activity
assay,whichassessesFVIIaexclusively[21],andhasalower
limitofquantiﬁcationof0.02 IU ml
-1andanassayprecision
of6%CV.TheFVIIaclotactivityassayismoreaccuratethan
the FVII:C assay, particularly at FVII concentrations below
6I Um l
-1 [15,22].
Results were generated using noncompartmental
analysis (NCA) and/or population pharmacokinetic analy-
sis of compartmental models (PopPK) (Table 1). The NCA
method requires rich concentration–time proﬁles for each
individual and is therefore not applicable where data are
limited.PopPKanalysisdoesnothavethisconstraint,allow-
ing even sparse proﬁles to be analyzed. All population
modelsusedinthePopPKanalysesofrFVIIahadﬁrst-order
elimination from the central compartment and baseline
to account for endogenous FVIIa production, if relevant.
A two-compartment population model was used for
healthy volunteers [12],one study of patients undergoing
orthotopic liver transplantation (OLT) [17], patients with
severe trauma [23] and patients with haemophilia.A one-
compartment model was used for one study of patients
undergoing OLT [20], patients with upper gastrointestinal
bleeding (UGIB) and patients undergoing liver resection.
rFVIIa in healthy volunteers
Several studies have examined the pharmacokinetics of
rFVIIa in healthy adult volunteers.The most recent showed
that healthy Japanese and Caucasian volunteers had com-
parable estimates of plasma clearance (33–37 ml kg
-1 h
-1),
terminal half-life (3.90–05.99 h
-1) and steady-state volume
of distribution (130–165 ml kg
-1). No sex-related differ-
ences in these parameters were observed [16]. These
results are consistent with those in healthy Caucasian vol-
unteers who were anticoagulated with acenocoumarol to
international normalized ratio 2–2.5 prior to dosing [11].
Analysis using a two-compartment model provided esti-
mates of half-life, clearance and steady-state volume of
distribution for doses above and below 20 mgk g
-1 [12].
Clearance rates of 31–35 ml kg
-1 h
-1 were reported, which
were comparable with those observed in the study by
Fridberg et al. [16].
rFVIIa in patients with minor tissue
injury and low-level bleeding
Adults with haemophilia A or B
Analysis of rFVIIa pharmacokinetics in adults with
haemophilia has demonstrated clearance rates of
32–39 ml kg
-1 h
-1, according to NCA [9, 15], and 29–
44 ml kg
-1 h
-1 according to PopPK (Jansen, data on ﬁle
2001;Kristensen,Klitgaard,data on ﬁle 2004).Pharmacoki-
netic data from Japanese adult patients with severe hae-
mophilia A or B and inhibitors were consistent with those
for Caucasian subjects [14], with a plasma half-life of 2.5–
5.0 h (mean 3.5 h) by NCA.
Children with haemophilia A or B
Analysis of rFVIIa pharmacokinetics in children with
haemophilia A [15] or haemophilia A or B [8] provided
estimated clearances of 58 and 67 ml kg
-1 h
-1 (NCA;FVII:C),
respectively. A similar clearance rate (60 ml kg
-1 h
-1)w a s
reported by PopPK analysis of data from Villar et al. [15]
(Kristensen,Klitgaard,data on ﬁle 2004).
Directcomparisonoftheresultsforadultsandchildren
(aged 18–55 and 2–12 years, respectively) by Villar et al.
[15] indicated that plasma clearance was signiﬁcantly
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6/65:1 / Br J Clin Pharmacol(P < 0.05;NCA) higher in paediatric patients than in adults,
using both the FVII:C and FVIIa clot activity assays.In con-
trast, there was only a nonsigniﬁcant trend towards an
increased volume of distribution in children compared
with adults and no difference in terminal half-life between
the two groups (both P > 0.05). Subsequent analysis of
these results by PopPK revealed no statistically signiﬁcant
(P > 0.01) differences in volumes of distribution between
adultsandchildrenforeitherassay,whileplasmaclearance
rates per kg body weight were higher in children (Kris-
tensen,Klitgaard,data on ﬁle 2004).This difference reﬂects
ahighermetabolicactivityinchildrenthaninadultsperkg
body weight and is possibly related to age-related differ-
ences in body composition, including differences in liver
volume per kg body weight,as previously described in the
literature [24, 25]. Mean population pharmacokinetic pro-
ﬁles for children and adults are shown in Figure 1,and the
relationship between clearance and weight is illustrated in
Figure 2.
In Villar et al. [15], children received ﬁrst 90 then
180 mgk g
-1 (after washout). Analysis of the effect of dose
demonstrated dose proportionality for the two rFVIIa
dosesevaluated.Thisisanimportantﬁnding,asitindicates
a predictable pharmacokinetic response in children to
changes in dose.
Patients with inherited FVII deﬁciency
In Berrettini et al. [13],rFVIIa 15 and 30 mgk g
-1 was admin-
istered to each patient (aged 20–43 years) with a 3-day
washout period between doses. No signiﬁcant dose-
dependent differences in clearance, half-life or volume of
distributionwereobserved(P > 0.05).Plasmaclearancerate
was71–79 ml kg
-1 h
-1andhencehigherthanthatobserved
inadultpatientswithhaemophiliaandinhealthysubjects.
rFVIIa in patients with cirrhosis
Patients with cirrhosis may have low concentrations of
coagulation factors, including FVII [26], resulting in a pro-
longed prothrombin time (PT).In a preliminary dose esca-
lation study, 10 patients with cirrhosis and prolonged PT
with no bleeding [10], received three successive doses
of rFVIIa (5,20 and 80 mgk g
-1) over 3 weeks.Plasma clear-
ance rates ranged from 33 to 44 ml kg
-1 h
-1, corres-
ponding to those for healthy adults and adults with
haemophilia; half-life ranged from 2.37 to 3.23 h. The
pharmacokinetic parameters assessed were independent
of dose (P > 0.05).
Patients with upper gastrointestinal bleeding
In contrast to nonbleeding patients with cirrhosis, the
clearance rate was 78 ml kg
-1 h
-1 after eight doses of
100 mgk g
-1 rFVIIa over a 30 h period in patients with cir-
rhosis and UGIB [19] (Klitgaard, data on ﬁle 2004). This is
approximately double that reported in healthy adults,and
was similar to clearance rates in patients with FVII deﬁ-
ciency (Klitgaard, data on ﬁle 2004). However, the half-
life (3.08 h) was within the range reported for healthy
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Figure 1
Population pharmacokinetic proﬁles of rFVIIa for patients with haemophilia A vs. time,following 90 mgk g
-1 (adults and children) and 180 mgk g
-1 (children
only) rFVIIa. Based on PopPK analysis of (A) FVIIa clot activity and (B) FVII:C activity in Villar et al. [15]. Adults 90 mgk g -1,(—); Children 90 mgk g -1, (– –);
Children 180 mgk g -1,( ---- )
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Br J Clin Pharmacol / 65:1 / 7adults. A preliminary open-label study in a similar patient
population reported a slightly lower half-life of 2–3 h fol-
lowing administration of a single dose of 80 mgk g
-1 rFVIIa
[18].
Patients undergoing orthotopic liver
transplantation
Two exploratory studies have assessed the effect of rFVIIa
in patients with cirrhosis undergoing OLT.In Planinsic et al.
[17], shortly after patients received a single dose of rFVIIa
before surgery, circulation through the liver was stopped,
and the liver was removed and replaced with the donor
liver, which was then reperfused. This enabled sub-
sequent assessment of clearance with and without circu-
lation through the liver. The results showed signiﬁcantly
(P < 0.005) different plasma clearance during periods of no
circulation (62 ml kg
-1 h
-1) vs. when the liver was perfused
(89 ml kg
-1 h
-1), while intercompartmental clearance was
unaffected by the absence of circulation through the liver
(P > 0.25) (Jansen,data on ﬁle 2001).Simulated population
pharmacokinetic proﬁles corresponding to phases with
and without liver circulation are illustrated in Figure 3.
Clearance rates under both conditions were higher than in
healthy volunteers and similar to those in patients with
cirrhosis and UGIB.
In Lodge et al. [20],patients received multiple doses of
rFVIIa immediately prior to ﬁrst incision, then every 2 h
until 30 min before anticipated liver reperfusion, with an
additional rFVIIa dose at the end of surgery. In a subse-
quent analysis of the study data by PopPK, clearance
was estimated to be 74 ml kg
-1 h
-1, in agreement with
Planinsic et al. [17] (Erichsen, Klitgaard, data on ﬁle 2004).
Analysis of the effect of a number of variables on plasma
clearance revealed a signiﬁcant effect (P < 0.01) of weight
and RBC transfusion requirements. Plasma clearance
increased by 4 ml kg
-1 h
-1 for each unit of RBC received,
and decreased by 1.3% for each kg change in body weight
below 75 kg.
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Figure 3
Population pharmacokinetic proﬁles of rFVIIa during phases with and
without liver circulation, for patients undergoing orthotopic liver trans-
plantation, following a single dose of 80 mgk g -1 rFVIIa. Analysis of data
from Planinsic et al. [17]. (Erichsen, Klitgaard, data on ﬁle 2004) No liver
circulation,(—);Liver circulation,(– –)
Weight (kg)
CL(Weight) [ml kg–1
 h–1] = 55.1 – 0.328 (Weight – 43.6) (P < 0.001)
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Figure 2
Individual estimates of clearance (CL) vs. weight for adult and paediatric patients with haemophilia,based on PopPK analysis of data from Villar et al. [15].
Estimated linear relationship between CL and weight based on FVIIa clot activity assay (full line, open circles) and FVII:C activity assay (dashed line, ﬁlled
circles).Based on FVIIa,(—);Based on FVII:C,( ---- )
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undergoing liver resection
In a further study by Lodge et al. [27],patients received 20
or80 mgk g
-1rFVIIabyslowinfusion5 minpriortoﬁrstskin
incision, with a second dose 5 h later if the surgery was
anticipated to last over 6 h. Clearance rate was approxi-
mately 64 ml kg
-1 h
-1 (NCA) and 70 ml kg
-1 h
-1 (PopPK) for
both doses (Klitgaard,data on ﬁle 2004).However,volume
of distribution increased signiﬁcantly (P < 0.001) with
dose.Analysis of the effect of various parameters on rFVIIa
pharmacokinetics found no signiﬁcant inﬂuence of RBC
transfusion requirement, blood loss during surgery,
weight, age or sex. Given that a two-compartment model
could not be estimated in the noncirrhotic patients, pos-
sibly due to the relatively short sampling duration, it is
conceivable that the one-compartment results are biased,
generatingahigherestimateofclearanceandaloweresti-
mate of half-life.
rFVIIa in patients with
severe trauma
Boffard et al. [2] and Klitgaard et al. [23] investigated
rFVIIa in two parallel, multicentre, randomized, placebo-
controlled studies in severe blunt and penetrating trauma.
Patients who received six units of RBCs within a 4-h period
were randomly assigned to receive either placebo or three
doses of rFVIIa (200, 100 and 100 mgk g
-1)a t0 ,1a n d3h ,
with the ﬁrst dose administered immediately after transfu-
sion of the eighth unit of RBC.Analysis by NCA of data for
patients who underwent frequent blood sampling follow-
ing rFVIIa dosing (n = 21) yielded clearance rates of 41 and
40 ml kg
-1 h
-1 for blunt and penetrating trauma, respec-
tively. PopPK analysis of the larger data set of patients
who underwent both frequent and less frequent blood
sampling (n = 230) gave an estimated clearance rate of
40 ml kg
-1 h
-1.
Further analysis revealed a signiﬁcant correlation
between clearance and 48 h RBC transfusion (P < 0.001).
Forty-eight h RBC requirement was used as a surrogate
marker for bleeding rate,as this cannot be accurately esti-
matedintraumapatients.Itshould,however,benotedthat
the 48 h RBC requirement may overestimate the actual
rate of bleeding during the 12 h pharmacokinetic sam-
pling period.
Using this model, a patient receiving no RBC transfu-
sions or 40 units of RBC after the ﬁrst dose of rFVIIa would
have a predicted clearance of approximately 36 ml kg
-1 h
-1
and 62 ml kg
-1 h
-1, respectively. The effect on the simu-
lated population pharmacokinetic proﬁles is illustrated in
Figure 4.The high variation in clearance, and the implica-
tions for the pharmacokinetic proﬁle, suggests that a
repeat dose regimen may be required for maintaining a
minimum effective FVII coagulant activity level through-
out this heterogeneous patient population.
Correlation between
pharmacokinetic parameters
and bleeding
Examination of plasma clearance values from studies of
rFVIIaacrossarangeofindications,fromhealthyvolunteers
to patients with severe trauma, suggests the existence of
two distinct populations. In healthy volunteers, plasma
clearance values were approximately 30–40 ml kg
-1 h
-1.
Plasma clearance values for adult patients with haemo-
philia,who typically are classiﬁed as having no bleeding or
onlylow-levelbleeding,andfornonbleedingpatientswith
cirrhosis are also within this ‘normal’ range. Clearance of
rFVIIa appears to be unaffected by dose in the range of
20–320 mgk g
-1.
In contrast, patients with liver disease and active, high
levels of bleeding (e.g. cirrhotic patients undergoing OLT
andnoncirrhoticpatientsundergoingmajorliverresection)
have much higher plasma clearance rates of between 60
and 90 ml kg
-1 h
-1.This is approximately twice that seen in
patients with low-level bleeding or healthy volunteers.
Moreover, in the OLT group, plasma clearance increased
signiﬁcantly after transplantation and during liver reperfu-
sion,aﬁndingwhichsupportsthehypothesisthattheliver
istheprincipalsiteofrFVIIametabolism[28].Theﬁndingof
anassociationbetweenincreasedRBCtransfusionrequire-
ment and increased clearance in trauma patients provides
further evidence to support the link between bleeding
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Figure 4
Population pharmacokinetic proﬁles of rFVIIa after administration of
three doses (200,100 and 100 mg/kg) at 0,1 and 3 h,simulated for various
postdose RBC transfusion requirements.Based on PopPK analysis of data
in trauma patients [23]. Figure adapted from [23] by kind permission of
BioMed Central. RBC = 8.7 units (mean), ( ); RBC = 20 units, (······);
RBC = 30 units,(– –);RBC = 4 0u n i t s ,( ---- )
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and plasma clearance values.
The relationship between RBC requirements and clear-
ance may well be multifactorial. In patients with massive
bleeding,thecombinationofcoagulationfactorconsump-
tion due to continued clot formation,loss due to ongoing
bleeding, and dilution due to ﬂuid and blood component
therapy may reduce the rFVIIa concentration to a poten-
tially suboptimal level for effective clot formation [29].
Furthermore, underlying liver disease seen in some of
these patients is likely to reduce the endogenous produc-
tion of a number of key coagulation factors,including FVII,
and may be associated with both thrombocytopenia and
platelet dysfunction [30]. It could be hypothesized that
reduced production of coagulation factors and functional
platelets may lead to ineffective or reduced coagulation.
However,the overall impact this may have on rFVIIa clear-
ance in the liver-diseased patient remains speculative.
Three other patient groups also had increased clear-
ance rates relative to normal levels, namely, patients with
congenitalFVIIdeﬁciency,paediatricpatientswithhaemo-
philia,and patients with UGIB and cirrhosis.
In patients with congenital FVII deﬁciency, increased
clearance rates of rFVIIa may be linked to the absence
of endogenous production of functional FVII/FVIIa.In hae-
mophilia A patients, following administration of rFVIIa
90 mgk g
-1, signiﬁcantly faster clearance was observed in
children compared with adults, suggesting that higher
dosesofrFVIIamaybeneededtoachievethesameplasma
concentrations as in adults [15]. Finally, in patients with
cirrhosis and UGIB, clearance was increased, although
bleeding and RBC transfusion requirements during the
period of pharmacokinetic sampling were relatively small
(average RBC requirement during ﬁrst 24 h: 0.9  1.8
units).At present it is not clear why the rFVIIa metabolism
appears to be altered in these patients.
It appears from these studies that plasma clearance
may provide more useful information than half-life for
assessingthebehaviourofrFVIIafollowingdosing.Half-life
estimates are often only based on a few terminal time-
points, and short sampling proﬁles may bias half-life esti-
mates downwards, as a pure elimination phase towards
the end of the pharmacokinetic proﬁle will not have been
recorded.In addition,mean plasma half-life estimates may
be affected by the modelling approach used to ﬁt the
available data.In contrast,plasma clearance is more robust
as a parameter for comparing rFVIIa pharmacokinetics
between patient groups.
In conclusion, this overview has demonstrated that
human subjects may be stratiﬁed into two distinct groups
in terms of rFVIIa pharmacokinetics. In one, comprising
healthy volunteers, adult patients with haemophilia and
nonbleeding patients with cirrhosis, plasma clearance is
relatively low (30–40 ml kg
-1 h
-1). In the other, comprising
children with haemophilia, patients with congenital FVII
deﬁciencyandpatientswithactive,highlevelsofbleeding,
plasma clearance appears to be higher (60–90 ml kg
-1 h
-1).
Differences in rFVIIa pharmacokinetics among patient
groups may have clinical implications in terms of how to
adapt the dosing regimen, depending on the expected
bleeding rate/blood loss and the underlying disease.
The authors wish to thank Paul Littlebury and Anne Stirland
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